ARTICLE

Goltz–Gorlin (focal dermal hypoplasia) and the microphthalmia with linear skin defects (MLS) syndrome: no evidence of genetic overlap

May-Britt Harmsen¹, Silvia Azzarello-Burri², M Mar García González³, Gabriele Gillissen-Kaesbach⁴, Peter Meinecke⁵, Dietmar Müller⁶, Anita Rauch⁷, Eva Rossier⁸, Eva Seemanova⁹, Christiane Spaich¹⁰, Bernhard Steiner², Dagmar Wiczorek¹¹, Martin Zenker⁷ and Kerstin Kutsche*,¹

¹Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; ²Institut für Medizinische Genetik, Universität Zürich, Schwerzenbach, Switzerland; ³Servei de Pediatria, Hospital de Figueres, Figueres, Spain; ⁴Institut für Humangenetik, Universität zu Lübeck, Lübeck, Germany; ⁵Medizinische Genetik, Altonaer Kinderkrankenhaus, Hamburg, Germany; ⁶Institut für Medizinische Genetik, Klinikum Chemnitz, Chemnitz, Germany; ⁷Humangenetisches Institut, Universitätsklinikum Erlangen, Erlangen, Germany; ⁸Medizinische Genetik, Universitätsklinikum Tübingen, Tübingen, Germany; ⁹Department of Clinical Genetics, Institute of Biology and Medical Genetics, Charles University, Prague, Czech Republic; ¹⁰Institut für Klinische Genetik, Klinikum Stuttgart, Stuttgart, Germany; ¹¹Institut für Humangenetik, Universitätsklinikum Essen, Essen, Germany

Focal dermal hypoplasia (FDH) is an X-linked developmental disorder with male lethality characterized by patchy dermal hypoplasia, skeletal and dental malformations, and microphthalmia or anophthalmia. Recently, heterozygous loss-of-function mutations in the *PORCN* gene have been described to cause FDH. FDH shows some clinical overlap with the microphthalmia with linear skin defects (MLS) syndrome, another X-linked male lethal condition, associated with mutations of *HCCS* in the majority of cases. We performed DNA sequencing of *PORCN* in 13 female patients with the clinical diagnosis of FDH as well as four female patients with MLS syndrome and no mutation in *HCCS*. We identified *PORCN* mutations in all female patients with FDH. Eleven patients seem to have constitutional *PORCN* alterations in the heterozygous state and two individuals are mosaic for the heterozygous sequence change in *PORCN*. No *PORCN* mutation was identified in the MLS-affected patients, providing further evidence that FDH and MLS do not overlap genetically. X chromosome inactivation (XCI) analysis revealed a random or slightly skewed XCI pattern in leukocytes of individuals with intragenic *PORCN* mutation suggesting that defective *PORCN* does not lead to selective growth disadvantage, at least in leukocytes. We conclude that the *PORCN* mutation detection rate is high in individuals with a clear-cut FDH phenotype and somatic mosaicism can be present in a significant proportion of patients with mild or classic FDH.

European Journal of Human Genetics (2009) 17, 1207–1215; doi:10.1038/ejhg.2009.40; published online 11 March 2009

Keywords: FDH; male-lethal; MIDAS; mosaicism; X-chromosomal dominant; X-inactivation

*Correspondence: Professor K Kutsche, Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, Campus Forschung, Martinistrasse 52, 20246 Hamburg, Germany.

Tel: +49 40 7410 54597; Fax: +49 40 7410 55138;

E-mail: kkutsche@uke.de

Received 29 July 2008; revised 9 February 2009; accepted 11 February 2009; published online 11 March 2009

Introduction

Focal dermal hypoplasia (FDH), also known as Goltz–Gorlin syndrome (MIM no. 305600), is a rare congenital ectomesodermal disorder characterized by a combination of skin defects, skeletal abnormalities, and ocular anomalies.¹ Affected individuals have patchy dermal hypoplasia, often

in a distribution pattern following the Blaschko's lines, and areas of subcutaneous fat herniation or deposition of fat into the dermis. In addition, sparse and brittle hair, hypoplastic nails and papillomas have been described. Skeletal abnormalities usually comprise syndactyly, ectrodactyly, and brachydactyly, and in some cases osteopathia striata has been seen. Patients with FDH frequently have ocular anomalies, including microphthalmia/anophthalmia, coloboma, and pigmentary and vascularization defects of the retina. Dental abnormalities, such as hypodontia, abnormal spacing of hypoplastic, or malformed teeth and enamel defects are often present.² FDH shows phenotypic overlap with the microphthalmia with linear skin defects (MLS) syndrome (MIM no. 309801). The most consistent features of MLS syndrome are microphthalmia with cloudy cornea or sclerocornea and linear skin defects restricted to the face and neck. Some patients also have agenesis of the corpus callosum, chorioretinal abnormalities, infantile seizures, congenital heart defect, and diaphragmatic hernia. Both FDH and MLS syndrome belong to the group of X-linked disorders with male lethality or reduced survival of affected males.³ In the early 1990s it has been hypothesized that FDH and MLS syndrome as well as Aicardi syndrome (MIM no. 304050), another X-linked condition characterized by CNS and eye abnormalities that mainly affects female patients are allelic disorders and represent variable outcomes of the same or a related genetic defect.^{4–6} Indeed, the three disorders are characterized by similar anomalies of the brain (agenesis of the corpus callosum), eye (microphthalmia, coloboma, and retinal pigmentary defects), and skin (linear skin defects) that has led to the hypothesis that the genes for these syndromes might be contiguous on the X chromosome.^{4,7} However, other authors were rebutting this concept and stated that MLS syndrome should be distinguished from FDH as marked clinical differences exist between the two disorders. For example, skin lesions are limited to the face and neck in MLS syndrome and skeletal abnormalities, such as clefting of hands or feet, and syndactyly are only present in patients with FDH.^{8,9}

Recently, the underlying genetic defects of FDH and MLS syndrome have been identified. Heterozygous mutations in the *HCCS* gene (Xp22.2), encoding the mitochondrial holocytochrome *c*-type synthase are responsible for MLS.¹⁰ In patients with FDH, heterozygous mutations in *PORCN*, located in Xp11.23, have been detected.^{11,12} Since the identification of *PORCN* as the gene responsible for FDH only four additional cases with novel intragenic *PORCN* alterations have been reported.^{13,14} *PORCN* codes for a member of the Porcupine protein family which are membrane-bound endoplasmatic reticulum proteins. Porcupine proteins are thought to be required for the attachment of long-chain fatty acids to Wnt proteins that is important for proper secretion of Wnt.^{15,16} The identification of different genes for FDH and MLS has provided

proof that the hypothesis of allelism was erroneous from the beginning. However, not all patients with clinical features highly suggestive of MLS and apparently normal karyotype have a detectable mutation in *HCCS* (K. Kutsche, unpublished data and Morleo *et al*¹⁷). This finding raises the question whether patients clinically diagnosed with MLS might in rare cases have a *PORCN* mutation due to clinical and/or genetic overlap between FDH and MLS.

Here, we present results of *PORCN* mutation screening in 13 female patients with FDH and four female patients displaying clinical manifestations compatible with the diagnosis of MLS syndrome, who had been previously tested negative for a mutation in *HCCS*.

Patients and methods

Subjects

We collected blood samples or received DNA from 13 female patients clinically diagnosed with FDH and four female patients with MLS syndrome (MLS1–4), who were assessed by experienced clinicians. Clinical information pertinent to the diagnosis was provided by the referring physicians. Table 1 summarizes the clinical findings of individuals with FDH.

MLS1 is a 2½-year-old girl and the first child of healthy parents. She was born at 43 weeks of gestation by natural delivery. The proposita's birth weight was 3570 g (10–50th centile), her body length 51 cm (10–50th centile), and she had an OFC of 34.5 cm (10th centile). At birth, linear erythematous lesions of the skin located on her face, ear lobes, and her left index finger were noticed. Sonography revealed absent corpus callosum and dilated ventricles. Seizures began at the age of 5 months. At 6 months of age, she underwent heart transplantation because of severe dilatative cardiomyopathy. At 15.5 months, her height and weight were below the 3rd centile, and she was microcephalic (OFC 41 cm, –4.6 SD). Dentition was markedly delayed. Ophthalmologic examination revealed myopia on the right eye as well as bilateral strabismus and nystagmus. Muscle tone was low at this age, and the girl was not able to sit without support.

Detailed clinical findings of a female patient MLS2 have previously been described.¹⁸ Briefly, she presented with some facial dysmorphic signs and showed linear cutaneous aplasia on her face and neck. Microphthalmia has also been noticed. Cardiac abnormalities included cardiomyopathy in terms of non-compaction myocard accompanied by Wolff–Parkinson–White syndrome. Her psychomotor development was normal.

Patient MLS3, a 5-year-old girl, is the first child of healthy parents. At 41 weeks of gestation, delivery was performed by caesarean section because of decelerating fetal heart rate. Body weight (2600 g) and length (45 cm) were below the 3rd centile, and OFC (32.5 cm) was at the 3rd centile. She presented with multiple linear necrotic

Table 1 Clinical data from 13 patients with the diagnosis of FDH

ILUGR, intrauterine growth retardation; LF, left foot; LH, left hand; (M), mosaic; NA, not analyzed; ND, not documented; RF, right foot; RH, right hand.

skin lesions on her face and neck along the lines of Blaschko. Moreover, the patient had a diaphragmatic hernia, renal agenesis on the left and an L-shaped (tandem) kidney on the right. Sonography of the brain disclosed a small corpus callosum. Echocardiographic analysis demonstrated hypertrophic cardiomyopathy and pulmonary hypertension. At age 15.5 months, she was microcephalic (OFC 42.5 cm, -3.4 SD) and showed the following dysmorphic facial signs: mild facial asymmetry with telecanthus and bilateral epicanthus, broad nasal bridge, smooth philtrum, small mandible, and mildly low-set and protruding ears with hypoplastic helices. Ophthalmologic evaluation revealed pigmentary defects of the retina as the only ocular abnormality. Other physical findings included lack of the 2nd incisor of the left maxilla, talipes on the right, and pes adductus on the left. The patient showed psychomotor retardation.

Only very limited clinical information was available for patient MLS4. MLS4 is a 2-year-old girl who presented with a skin defect on her forehead, microphthalmia/anophthalmia, and an atypical facial cleft.

By routine chromosome analysis, a normal female karyotype with 46,XX was identified in the four patients with MLS syndrome. These individuals had previously been tested negative for mutations in *HCCS* (PCR and sequencing as well as copy number analysis by quantitative PCR; data not shown). Analysis of the X chromosome inactivation (XCI) status using the androgen receptor assay revealed severely skewed XCI in all four patients with a pattern ranging from 96:4 to 100:0 (K. Kutsche, unpublished data) that is in line with extensive XCI skewing in patients with MLS and *HCCS* mutation.^{10,19}

Ethical approval for this study was obtained and informed consent for the genetic analyses was received from parents or their legal guardians.

Mutation and SNP analysis

We isolated genomic DNA from blood lymphocytes of the patients and parents by standard procedures. We amplified the coding region including the flanking intronic sequences of the *PORCN* gene (14 exons; GenBank accession no. NM_203475) from genomic DNA. Primer sequences are available on request. Amplicons were directly sequenced using the ABI BigDye Terminator Sequencing Kit (Applied Biosystems, Weiterstadt, Germany) and an automated capillary sequencer (ABI 3130; Applied Biosystems). Where mutations were shown to have arisen *de novo*, we verified declared relationships by genotyping of both parents and the patient at 10 microsatellite loci.

For FDH4 and 7, the PCR product with the mutation was cloned in the pCR2.1 TOPO TA Cloning Vector (Invitrogen, Karlsruhe, Germany). Individual *E.coli* clones were picked and subjected to colony PCR using standard protocols. PCR products were analyzed by the single-strand conformational polymorphism (SSCP) method. Individual fragments

that were assigned to either of the two different banding patterns were sequenced.

Calculation of splicing efficiencies

Splicing efficiencies of the normal *versus* the newly introduced splice acceptor site in intron 4 of *PORCN* were calculated by use of three splice prediction programs: SpliceView (<http://bioinfo.itb.cnr.it/oriel/splice-view.html>), the Berkely Drosophila Genome Project (BDGP) (<http://www.fruitfly.org>), and NetGene2 (<http://www.cbs.dtu.dk/services/NetGene2/>).

PORCN transcript analysis

Fresh venous blood samples (2.5 ml) were collected into PAXgene Blood RNA Tubes (PreAnalytiX; QIAGEN, Hilden, Germany). Total RNA was extracted by use of the PAXgene Blood RNA Kit (QIAGEN) according to the manufacturer's instructions. 1 µg of RNA was reverse transcribed into cDNA (Superscript II; Invitrogen) using random hexanucleotides (Invitrogen) according to the manufacturer's protocol. RT-PCR fragments were obtained by the use of forward primer *PORCN*-ex4F (5'-CACATGGTAGACACCGT AGACATGG-3') and reverse primer *PORCN*-ex5R (5'-GGTA GCTGTGGAAGGATATCCAGG-3') according to standard PCR protocols. PCR products of patient FDH5 were cloned into pCR2.1 TOPO TA Cloning Vector (Invitrogen). *E.coli* clones were subjected to colony PCR and PCR products from individual clones were sequenced.

X chromosome inactivation assay

Quantitative examination of the methylation pattern at the *AR* locus was performed as described earlier.¹⁰

Results

We performed mutation analysis of *PORCN* in 13 female patients with the clinical diagnosis of FDH (Figure 1) and four patients with MLS syndrome, previously tested negative for a mutation in *HCCS*. In total, we identified 12 different heterozygous intragenic mutations of *PORCN* in the 13 patients with FDH and no sequence variation in patients with MLS. Of these sequence alterations seven are nonsense and two missense mutations, two are small rearrangements, and one is a putative splice mutation (c.374-46T>A) (Table 2). Three of the mutations (p.W74X, p.R90X, and p.R243X) have been established as pathogenic sequence alterations,^{11,12} whereas nine are novel (Table 2). In three individuals (FDH1, 8, and 10) with a novel mutation, we could demonstrate *de novo* occurrence of the mutation (including confirmation of paternity) (Table 2). For the remaining six individuals who carry none of the reported *PORCN* alterations, parental DNA was not available. Nonetheless, these mutations were not found in at least 204 control X chromosomes (Table 2).

Figure 1 Clinical features of FDH. Patients FDH11 (a–e), FDH1 (g), FDH6 (h–j), and FDH10 (k) show the typical clinical findings of FDH, such as dermal hypoplasia (leg of FDH 7 as newborn in (h) and at age 8 years in (i)), hyperpigmentation along the lines of Blaschko (c and i) and severe skeletal malformations, in particular syndactyly (d and e). Dysmorphic ears (b, j, and k) as well as dental defects such as oligodontia, hypodontia, enamel hypoplasia, and notched incisors (g) in FDH1. The father of patient FDH11 shows mild linear skin lesions on his calf (f).

Table 2 *PORCN* mutations and X chromosome inactivation (XCI) pattern in 13 patients with FDH

Patient	Exon	Nucleotide substitution	Amino acid change	Novel	de novo	Analyzed control X chromosomes	XCI	Comments
FDH10	2	c.49dupT	p.C17LfsX11	+	+	—	54:46	—
FDH3a	3	c.166_167dupAC	p.V57PfsX60	+	—	204	83:17	—
FDH3b	3	c.166_167dupAC	p.V57PfsX60	+	Familial ^a	204	80:20	—
FDH6	3	c.221G>A	p.W74X	—	+	—	76:24	—
FDH4	3	c.268C>T	p.R90X	—	+	—	37:63	Mosaic
FDH5	intron 4	c.374-46T>A	—	+	—	380	86:14	Altered splicing
FDH9	5	c.509G>A	p.W170X	+	Familial ^b	212	34:66	—
FDH12	9	c.727C>T	p.R243X	—	—	—	NI	—
FDH8	12	c.1082A>T	p.E361V	+	+	—	62:38	—
FDH11	13	c.1154G>A	p.C385Y	+	Familial ^c	212	55:45	—
FDH7	14	c.1186C>T	p.R396X	+	—	216	41:59	Mosaic
FDH2	15	c.1290C>A	p.Y430X	+	—	216	58:42	—
FDH1	15	c.1317G>A	p.W439X	+	+	—	47:53	—

NI, not informative.

^aMother (FDH3a)-to-daughter (FDH3b) transmission.

^bMother and possibly maternal grandmother affected by history.

^cFather shows mild clinical features of FDH, but did not carry the mutation in DNA isolated from leukocytes.

The majority of patients were sporadic cases. However, in an affected mother–daughter duo (FDH3a and b) we detected the 2-bp duplication c.166_167dupAC in exon 3

and in patient FDH9, who was reported to have an affected mother and possibly also a maternal grandmother, the c.509G>A transition was identified which leads to a

premature stop codon (p.W170X) (Table 2). Patient FDH11 was found to carry the c.1154G>A transition in the heterozygous state, predicting a substitution of the evolutionary highly conserved amino acid cysteine at position 385 by tyrosine (p.C385Y). The father of this patient had mild linear skin lesions on his calf (Figure 1f) and osteopathia striata, both clinical features typical of FDH suggesting somatic mosaicism. However, we could not detect the mutant base (adenine) in DNA extracted from blood cells of the father (no other material was available for testing).

In two individuals, FDH4 and 7 with c.268C>T (p.R90X) and c.1186C>T (p.R396X), respectively, the sequence profiles showed very low signals for the mutant variant superimposed on the wild-type sequence suggesting that the mutations are present in a mosaic state (Figure 2). The respective PCR product of each patient was subcloned and individual clones (PCR products) were subjected to SSCP analysis. We observed two banding patterns for the PCR products of each cloned amplicon. By DNA sequence analysis of selected clones we could assign the wild-type and the mutant sequence to either of the two banding patterns and identified a ratio of 9/53 (~17%; mutant *versus* wild-type sequence) for the c.268C>T transition

(FDH4) and 6/56 (~11%) for the c.1186C>T alteration (FDH7) (data not shown), confirming the mosaic status of these patients.

In patient FDH5, we detected the only non-coding change, c.374-46T>A, in intron 4 which could create a novel splice acceptor site (TG>AG). FDH5 showed typical clinical features of FDH, such as linear skin lesions, microphthalmia, coloboma, syn- and polydactyly, nail dysplasia, cleft palate, auricle dysplasia, and microcephaly (Table 1). Therefore, we investigated the effect of this sequence change on splicing. *In silico* analysis using three splice site prediction programs revealed a low efficiency (if at all) for the normal acceptor site, whereas the newly introduced splice site was efficiently recognized by all programs (Figure 3a) suggesting that this site might also be used *in vivo*. Next, we analyzed *PORCN* transcripts by generating an RT-PCR product with primers located in exons 4 and 5 and obtained an amplicon with the expected size of 193 bp in patient FDH5 and two healthy individuals (Figure 3b). In addition, a larger PCR product of about 50 bp was observed in the patient and not in control individuals (Figure 3b). Subcloning and direct sequencing of both amplicons of FDH5 demonstrated splicing of exon 4 to exon 5 in the 193-bp amplicon (Figure 3c). However, an insertion of 44 bp between the last nucleotide of exon 4 and the first base of exon 5 was found in the larger PCR product (Figure 3d). These data show that use of the novel splice site located 46 bp upstream of the normal acceptor site in intron 4 causes an out-of-frame insertion of 44 intronic nucleotides in the *PORCN* mRNA.

We analyzed the XCI pattern in the DNA isolated from leukocytes of all female patients with a sequence alteration in *PORCN* and identified random or slightly skewed (approximately 85:15) XCI (Table 2).

Discussion

We identified pathogenic mutations in *PORCN* in 13 female patients with FDH, with exons 3, 9, 10, and 12 representing mutational hot spots (this work and Grzeschik *et al*¹¹, Wang *et al*¹², Clements *et al*¹³, Leoyklang *et al*¹⁴). These data confirm that *PORCN* is the major gene, if not the unique one, for the classic FDH phenotype. Eleven of these patients appear to carry a constitutional mutation in the heterozygous state, whereas in two patients *PORCN* alterations represent a postzygotic mutation resulting in somatic mosaicism. *De novo* mosaic mutations have been suggested to be associated with a milder phenotypic outcome.¹¹ Although this applies to patient FDH7 (Table 1), FDH4 with the mosaic nonsense mutation c.268C>T (p.R90X) showed the majority of FDH-typical characteristics (Table 1). These data suggest that a mosaic *PORCN* mutation found in leukocytes does not necessarily correlate with a mild phenotype in affected patients. Rather the relative abundance of the mutation in

Figure 2 Sequencing profiles from patients FDH4 (exon 3; left) and FDH7 (exon 14; right) with mosaic *PORCN* mutations. Top: profiles of directly sequenced PCR products suggestive of mosaicism for the c.268C>T mutation in FDH4 and c.1186C>T in FDH7. Middle: representative sequence of cloned PCR amplicons with wild-type sequence. Bottom: representative sequence of mutant cloned PCR products. The mutated and normal base is indicated by an orange arrow. Coding triplets and corresponding amino acid residues (one-letter code) are indicated.

Figure 3 The c.374-46T>A mutation in patient FDH5 introduced a novel splice acceptor site in *PORCN* intron 4. (a) Two of three splice site prediction programs failed to recognize the wild-type splice acceptor site, whereas the novel splice site yielded high scores by all three programs. (b) RT-PCR products were amplified from cDNA of patient FDH5 and two healthy individuals (C1 and C2) with primers located in *PORCN* exons 4 and 5. The normal 193-bp product is present in FDH5 and two controls, however, an additional amplicon of ~240 bp was only amplified from the cDNA of FDH5 (white arrow). (c) Part of the sequence profile of the wild-type cloned RT-PCR amplicon (193 bp) showed splicing of exon 4 (ex 4) to exon 5 (ex 5). (d) Sequence analysis of the mutant cloned RT-PCR product (237 bp) revealed 44 bp of intron 4 spliced between exon 4 and 5. Coding triplets and corresponding amino acid residues (one-letter code) are indicated.

specific developing tissues, such as skin, bone, and eye seems to be relevant for development of a full-blown or mild phenotype. In the father of patient FDH11 with mild clinical features of FDH we could not detect somatic mosaicism of the missense mutation (c.1154G>A/p.C385Y) identified in his severely affected daughter. In contrast, in the affected father–daughter duo reported by Wang *et al*,¹² the c.1059_1071dup13 mutation was found in the female patient with FDH in the heterozygous and in her mildly affected father in a mosaic state in DNA isolated from peripheral blood leukocytes. We propose that DNA isolated from other tissues than blood lymphocytes, if available, should be analyzed for the presence of a mosaic *PORCN* mutation in mildly affected cases with several typical features of FDH.

By *PORCN* transcript analysis we demonstrated *in vivo* recognition of a novel splice acceptor site 46 bp upstream of the natural acceptor site in intron 4 of patient FDH5 due to the c.374-46T>A mutation. Insertion of 44 intronic nucleotides in the *PORCN* mRNA most likely results in a functionally impaired protein harbouring 14 *PORCN*-unrelated amino acids after arginine 124 and lacking 338 *PORCN* residues at the COOH terminus. Although we did not determine the ratio (percentage) of the newly created splice site usage, this splice acceptor might be used with

high efficiency based on the severe phenotype of FDH5 (Table 1) and its efficient recognition by three splice prediction programs (Figure 3a).

We identified random or slightly skewed XCI in our patients with a heterozygous intragenic *PORCN* mutation that is in line with random XCI in the majority of mutation-positive patients with FDH.^{11,12,14} This data suggests that *PORCN* does not seem to be critical for cell division or survival, otherwise cells with the mutated X chromosome active would fail to divide or survive, eventually leading to severe skewing of XCI. However, in female patients with a microdeletion covering *PORCN* skewed XCI has been consistently observed.^{11,12,20} Nonetheless, this finding is not surprising as one or more of the neighbouring genes (proteins) in the deleted interval, such as *SLC38A5*, *FTSJ1*, or *OATL1* could account for selective survival of cells with the wild-type X chromosome active.^{11,12} Indeed, skewed XCI has been found in a healthy female patient who carries a heterozygous 50-kb deletion encompassing the two genes *SLC38A5* and *FTSJ1*.²¹ This data suggests that lack of *SLC38A5* or *FTSJ1* cause a growth disadvantage of cells with the mutation on the active X chromosome leading to skewed XCI in female patients heterozygous for a mutation in *SLC38A5* or *FTSJ1*. It has been proposed that the pattern of XCI, not

only in blood cells but also in other tissues influences the development of clinical features in female patients with an X-linked male lethal disorder resulting in a high phenotypic variability (from the most severe phenotype to a milder manifestation or the total absence of clinical features).¹⁹ Similarly, the phenotype also varies in female patients with a microdeletion including *PORCN* (as well as *SLCA38A5* and *FTSJ1*) and skewed XCI. Typical clinical features of FDH, such as linear skin lesions, dermal hypoplasia, nail dystrophy, and asymmetric bone defects, but no ocular abnormalities have been observed in five sporadic female patients with a submicroscopic deletion encompassing *PORCN* and additional genes.^{11,12} A 112-kb deletion including *PORCN* was found in four female patients from a three-generation family with localized subepidermal telangiectasias following Blaschko's lines (angioma serpiginosum), a rare skin disorder that has been suggested to be allelic to FDH.^{20,22} Taken together, female patients with an intragenic *PORCN* mutation and random XCI are supposed to show the classical FDH phenotype. In these cases, somatic mosaicism can lead to a milder phenotype. In contrast, female patients with a microdeletion covering *PORCN* and another gene, that causes selective growth disadvantage when absent, may show higher phenotypic variability, including unusual mild phenotypes that could be due to severe skewing of XCI. Thus, the phenotype in female patients heterozygous for a pathogenic X-linked mutation can be influenced by several different mechanisms, such as factors related to the X inactivation process,^{23–25} somatic mosaicism,^{11,12} and the nature of the mutation,²⁴ suggesting that establishing a genotype–phenotype correlation is difficult, if not impossible, in these disorders.

One important finding of this study is the absence of a *PORCN* mutation in patients with MLS syndrome, who had been tested negative for mutations in the established disease gene *HCCS*. Two of these patients (MLS1 and 3) did not show the classical MLS phenotype as microphthalmia was absent. However, the presence of other clinical features, such as corpus callosum hypo- or aplasia, cardiomyopathy, and diaphragmatic hernia strongly suggested that the phenotype of these patients belongs to the MLS spectrum. Although we cannot exclude the presence of cryptic alterations such as changes in an intron, the 5'- or 3'-untranslated region, or defects in the promoter region or *cis*-regulatory element of either *HCCS* or *PORCN*, our negative findings indicate that mutations of *PORCN* are not involved in the aetiology of MLS. Thereby, we confirm the concept that MLS and FDH are not allelic and also exclude the possibility that one of the four patients had FDH rather than MLS. In addition, severely skewed XCI in the four *PORCN*- and *HCCS*-mutation negative individuals with a phenotype strongly resembling MLS may provide at least some evidence for X-linked genetic heterogeneity in this disease.

Taken together, our data suggest that (i) FDH is a clinically and genetically homogeneous disorder and in patients with a clear-cut FDH phenotype a *PORCN* mutation most likely will be identified, (ii) somatic mosaicism can be present in patients with a mild or classic FDH phenotype and particular attention should be paid to this phenomenon when diagnostic testing is performed, (iii) *PORCN* deficiency itself does not cause lethality of leukocytes with the mutation on the active X chromosome, and (iv) MLS and FDH are different entities, both from the clinical and genetic point of view.

Acknowledgements

We are grateful to the patients and their parents. The results summarized here are part of the MD thesis of May-Britt Harmsen at the University of Hamburg. We thank Inka Jantke for skillful technical assistance, Isabella Wimplinger for sequence analysis of *HCCS* and X chromosome inactivation analysis, Manuela Morleo and Brunella Franco for copy number analysis of *HCCS* exons, and Stephan Schneider for his constant support to obtain material from patient FDH5.

References

- Goltz RW, Peterson WC, Gorlin RJ, Ravits HG: Focal dermal hypoplasia. *Arch Dermatol* 1962; **86**: 708–717.
- Goltz RW: Focal dermal hypoplasia syndrome. An update. *Arch Dermatol* 1992; **128**: 1108–1111.
- Van den Veyver IB: Microphthalmia with linear skin defects (MLS), Aicardi, and Goltz syndromes: are they related X-linked dominant male-lethal disorders? *Cytogenet Genome Res* 2002; **99**: 289–296.
- Ballabio A, Andria G: Deletions and translocations involving the distal short arm of the human X chromosome: review and hypotheses. *Hum Mol Genet* 1992; **1**: 221–227.
- Lindsay EA, Grillo A, Ferrero GB *et al*: Microphthalmia with linear skin defects (MLS) syndrome: clinical, cytogenetic, and molecular characterization. *Am J Med Genet* 1994; **49**: 229–234.
- Naritomi K, Izumikawa Y, Nagataki S *et al*: Combined Goltz and Aicardi syndromes in a terminal Xp deletion: are they a contiguous gene syndrome? *Am J Med Genet* 1992; **43**: 839–843.
- Donnenfeld AE, Graham Jr JM, Packer RJ, Aquino R, Berg SZ, Emanuel BS: Microphthalmia and chorioretinal lesions in a girl with an Xp.22.2-pter deletion and partial 3p trisomy: clinical observations relevant to Aicardi syndrome gene localization. *Am J Med Genet* 1990; **37**: 182–186.
- Happle R, Daniels O, Koopman RJ: MIDAS syndrome (microphthalmia, dermal aplasia, and sclerocornea): an X-linked phenotype distinct from Goltz syndrome. *Am J Med Genet* 1993; **47**: 710–713.
- Mücke J, Happle R, Theile H: MIDAS syndrome respectively MLS syndrome: a separate entity rather than a particular lyonization pattern of the gene causing Goltz syndrome. *Am J Med Genet* 1995; **57**: 117–118.
- Wimplinger I, Morleo M, Rosenberger G *et al*: Mutations of the mitochondrial holocytochrome c-type synthase in X-linked dominant microphthalmia with linear skin defects syndrome. *Am J Hum Genet* 2006; **79**: 878–889.
- Grzeschik KH, Bornholdt D, Oeffner F *et al*: Deficiency of *PORCN*, a regulator of Wnt signaling, is associated with focal dermal hypoplasia. *Nat Genet* 2007; **39**: 833–835.
- Wang X, Reid Sutton V, Omar Peraza-Llanes J *et al*: Mutations in X-linked *PORCN*, a putative regulator of Wnt signaling, cause focal dermal hypoplasia. *Nat Genet* 2007; **39**: 836–838.

- 13 Clements SE, Wessagowit V, Lai-Cheong JE, Arita K, McGrath JA: Focal dermal hypoplasia resulting from a new nonsense mutation, p.E300X, in the PORCN gene. *J Dermatol Sci* 2008; **49**: 39–42.
- 14 Leoyklang P, Suphapeetiporn K, Wananukul S, Shotelersuk V: Three novel mutations in the PORCN gene underlying focal dermal hypoplasia. *Clin Genet* 2008; **73**: 373–379.
- 15 Takada R, Satomi Y, Kurata T *et al*: Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. *Dev Cell* 2006; **11**: 791–801.
- 16 Willert K, Brown JD, Danenberg E *et al*: Wnt proteins are lipid-modified and can act as stem cell growth factors. *Nature* 2003; **423**: 448–452.
- 17 Morleo M, Pramparo T, Perone L *et al*: Microphthalmia with linear skin defects (MLS) syndrome: clinical, cytogenetic, and molecular characterization of 11 cases. *Am J Med Genet A* 2005; **137**: 190–198.
- 18 Kherbaoui-Redouani L, Eschard C, Bednarek N, Morville P: (Cutaneous aplasia, non compaction of the left ventricle and severe cardiac arrhythmia: a new case of MLS syndrome (microphthalmia with linear skin defects)). *Arch Pediatr* 2003; **10**: 224–226.
- 19 Morleo M, Franco B: Dosage compensation of the mammalian X chromosome influences the phenotypic variability of X-linked dominant male-lethal disorders. *J Med Genet* 2008; **45**: 401–408.
- 20 Houge G, Oeffner F, Grzeschik KH: An Xp11.23 deletion containing PORCN may also cause angioma serpiginosum, a cosmetic skin disease associated with extreme skewing of X-inactivation. *Eur J Hum Genet* 2008; **16**: 1027–1028.
- 21 Froyen G, Bauters M, Boyle J *et al*: Loss of SLC38A5 and FTSJ1 at Xp11.23 in three brothers with non-syndromic mental retardation due to a microdeletion in an unstable genomic region. *Hum Genet* 2007; **121**: 539–547.
- 22 Blinkenberg EO, Brendehaug A, Sandvik AK, Vatne O, Hennekam RC, Houge G: Angioma serpiginosum with oesophageal papillomatosis is an X-linked dominant condition that maps to Xp11.3-Xq12. *Eur J Hum Genet* 2007; **15**: 543–547.
- 23 Franco B, Ballabio A: X-inactivation and human disease: X-linked dominant male lethal disorders. *Curr Opin Genet Dev* 2006; **16**: 254–259.
- 24 Migeon BR: Why females are mosaics, X-chromosome inactivation, and sex differences in disease. *Genet Med* 2007; **4**: 97–105.
- 25 Van den Veyver IB: Skewed X inactivation in X-linked disorders. *Semin Reprod Med* 2001; **19**: 183–191.